Comparing Check-Cap (MBAI) and Its Peers

Check-Cap (NASDAQ:MBAI) is one of 28 public companies in the “Surgical, Medical, And Dental Instruments And Supplies” industry, but how does it weigh in compared to its competitors? We will compare Check-Cap to similar companies based on the strength of its valuation, dividends, profitability, analyst recommendations, institutional ownership, risk and earnings.

Institutional and Insider Ownership

1.1% of Check-Cap shares are held by institutional investors. Comparatively, 19.3% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are held by institutional investors. 0.5% of Check-Cap shares are held by insiders. Comparatively, 19.5% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Volatility & Risk

Check-Cap has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500. Comparatively, Check-Cap’s competitors have a beta of 1.76, suggesting that their average stock price is 76% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Check-Cap and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Check-Cap	1	0	0	0	1.00
Check-Cap Competitors	79	79	155	6	2.28

As a group, “Surgical, Medical, And Dental Instruments And Supplies” companies have a potential upside of 33.96%. Given Check-Cap’s competitors stronger consensus rating and higher probable upside, analysts plainly believe Check-Cap has less favorable growth aspects than its competitors.

Profitability

This table compares Check-Cap and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Check-Cap	N/A	N/A	N/A
Check-Cap Competitors	-570.12%	-153.34%	-54.42%

Valuation and Earnings

This table compares Check-Cap and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Check-Cap	N/A	-$25.15 million	-0.59
Check-Cap Competitors	$61.66 million	-$32.15 million	5.33

Check-Cap’s competitors have higher revenue, but lower earnings than Check-Cap. Check-Cap is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

Check-Cap competitors beat Check-Cap on 9 of the 13 factors compared.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient’s back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. The company was incorporated in 2004 and is based in Isfiya, Israel.